Humacyte’s (HUMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note released on Wednesday morning,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright also issued estimates for Humacyte’s FY2024 earnings at ($1.36) EPS and FY2025 earnings at ($0.77) EPS.

A number of other equities research analysts also recently issued reports on HUMA. Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. TD Cowen restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Humacyte Stock Performance

Shares of NASDAQ HUMA opened at $4.84 on Wednesday. Humacyte has a 12 month low of $2.35 and a 12 month high of $9.97. The company has a 50-day simple moving average of $5.42 and a 200-day simple moving average of $6.17. The company has a market cap of $577.06 million, a PE ratio of -3.61 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.10 and a quick ratio of 5.41.

Humacyte (NASDAQ:HUMA) last released its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, equities analysts anticipate that Humacyte will post -1.22 earnings per share for the current year.

Insider Buying and Selling at Humacyte

In other news, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. The trade was a 5.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the transaction, the director now directly owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last ninety days. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Endowment Wealth Management Inc. boosted its stake in Humacyte by 3.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after acquiring an additional 3,000 shares during the last quarter. nVerses Capital LLC bought a new position in Humacyte during the 2nd quarter valued at $28,000. Private Advisor Group LLC boosted its stake in Humacyte by 1.8% during the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after acquiring an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after purchasing an additional 8,557 shares during the period. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Humacyte by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares during the period. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.